"Deadly cholesterol that doesn’t show up on routine tests is slashed by 94% with single dose of new drug"

Joseph · 2025-04-01T12:22:00.198Z

The PR…

By Diana Bruk

Published March 31, 2025, 1:43 p.m. ET

Deadly cholesterol that doesn’t show up on routine tests is slashed by...

“This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.”

Link to the papers abstract below, the full paper requires regi$tration.

Original Article

“Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)”

https://www.nejm.org/doi/full/10.1056/NEJMoa2415818

Additional reading;

“Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)”

A Randomized Dose-Ascending Clinical Trial

PubMed Central (PMC)

Lepodisiran, an Extended-Duration Short Interfering RNA Targeting...

What is the safety and tolerability of lepodisiran, which is a short interfering RNA directed at hepatic production of apolipoprotein(a), and the effect on lipoprotein(a) serum concentrations at doses from 4 mg to 608 mg through 336 days (48 weeks)...